Akeso's Ivonescimab Achieves Positive OS Results in Phase III First-Line Biliary Tract Cancer Trial
nashnova research
Akeso announced that its bispecific antibody ivonescimab met the overall survival (OS) primary endpoint in a Phase III trial for first-line advanced biliary tract cancer — marking the drug's first positive Phase III result outside lung cancer and validating its expansion into gastrointestinal tumors.
What exactly did this trial prove?
Trial AK112-309 enrolled 682 patients with advanced biliary tract cancer in a randomized, double-blind, controlled design — the gold standard for regulatory approval.
Ivonescimab plus chemotherapy was tested against durvalumab (a PD-L1 inhibitor) plus chemotherapy. The Independent Data Monitoring Committee (IDMC) confirmed at a pre-specified interim analysis: the OS primary endpoint was met with statistically significant and clinically meaningful benefit.
In plain terms = compared with the current standard regimen, patients on ivonescimab lived longer — and the gap was too large to be coincidence.
Why is this result especially important for ivonescimab?
Ivonescimab is the world's first PD-1/VEGF bispecific antibody — a drug that blocks two tumor-growth pathways at once. All 4 prior Phase III wins were in lung cancer.
This means → the biliary tract cancer data is ivonescimab's first Phase III positive outside the lungs, proving the dual-target mechanism works beyond one organ and extending the expansion logic toward a broader class of solid tumors.
The trial also hit progression-free survival (PFS) and objective response rate (ORR) — all key secondary endpoints positive. A clean sweep strengthens the regulatory filing package.
How many approved indications does ivonescimab already hold?
China's NMPA has approved three indications, all in lung cancer: May 2024 for second-line EGFR-mutant non-squamous NSCLC; April 2025 for first-line PD-L1-positive advanced NSCLC; August 2026 for first-line squamous NSCLC.
Two of those lung cancer indications are already on the national reimbursement list. This reflects a drug already in its commercial ramp-up phase for lung cancer.
In plain terms = lung cancer is the "established brand already generating revenue"; biliary tract cancer is "the new front that just got its report card."
What comes next?
Ivonescimab is being studied across more than 40 indications — biliary tract, head-and-neck squamous, triple-negative breast, colorectal, pancreatic, and urothelial cancers among them — with 60 Phase II/III trials underway, of which 16 are registrational.
This means → if the biliary tract cancer indication clears approval and wins reimbursement, it creates a template for the GI and broader solid-tumor pipeline behind it.
Full data have not yet been disclosed and will be presented at future international conferences and in journals — data quality and safety details are still pending, and the market's pricing of commercialization potential will only sharpen once those numbers are public.
市场有风险，内容仅供研究参考，不构成投资建议。